Compare ACADIA Pharmaceuticals Inc. (ACAD) vs eBay Inc (EBAY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs eBay Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.85 (market cap $4.49B), while eBay Inc trades at $114.47 (market cap $50.94B). The key difference: eBay Inc is far larger — about 11.3× ACADIA Pharmaceuticals Inc.'s market cap, and eBay Inc pays a 1.08% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | EBAY | |
|---|---|---|
Market Cap | $4.49B | $50.94B |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $118.96 |
52-Week Low | $20.06 | $75.33 |
Enterprise Value | $3.69B | $54.28B |
Volume | — | 5,186,418 |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
EBAY trades at $114.71, down slightly by 0.11% today. The stock shows strong profitability with a 17.61% net income margin and has beaten earnings estimates for three consecutive quarters. Technical indicators are bullish, with the price above key moving averages. Recent news highlights GameStop's unsolicited takeover interest, adding speculative momentum. Cash flow turned negative in 2025 but is projected to recover in 2026.
The outlook is mixed: solid fundamentals and earnings beats support upside, but the stock trades above the analyst consensus target of $109.50. Risks include takeover uncertainty and competitive pressures. Wall Street sentiment is neutral with a slight buy bias, though valuation multiples like P/E of 26.25 suggest limited near-term growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About eBay Inc
eBay Inc. is a global commerce company. The Company's platforms are designed to enable sellers worldwide to organize and offer their inventory for sale and buyers to find and buy it. eBay's items can be new or used, plain or luxurious, commonplace or rare, trendy or one-of-a-kind.
Read more on EBAY →
